Monte Rosa Therapeutics, Inc. (GLUE) has an overall financial health rating of C with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2026-04-07.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-04-07 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-04-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-04-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-04-01 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-31 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-30 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-25 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-23 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
